Traduction de «ranges from » (Néerlandais → Français) :

It ranges from > 30% (and is still rising) in countries like the UK, France, Italy, Spain and Portugal, to less than 2% in the Netherlands and Scandinavia, where a rigid national policy is in place.
Elle s'étend à plus de 30%, et continue encore à augmenter dans des pays comme le R-U, la France, l'Italie, l'Espagne et le Portugal, à moins de 2% dans les Pays-Bas et la Scandinavie où est appliquée une politique nationale rigide.

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

The reason behind this ambition is certainly not obvious: the competent medicines authorities in other Member States have the same ambition and vaccinology is, in epidemiological terms, a very broad domain, ranging from the prevention of neonatal pathology to hospital infections to sexually transmitted diseases.
The reason behind this ambition is certainly not obvious: the competent medicines authorities in other Member States have the same ambition and vaccinology is, in epidemiological terms, a very broad domain, ranging from the prevention of neonatal pathology to hospital infections to sexually transmitted diseases.

The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.
The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.

IRPA (1984), " Interim guidlines on limits of exposure to radiofrequency electromagnetic fields in the frequency range from 100 kHz to 300 GHz" , Health Physics 46, p.975-984.
IRPA (1984), " Interim guidlines on limits of exposure to radiofrequency electromagnetic fields in the frequency range from 100 kHz to 300 GHz" , Health Physics 46, p975-984.

Moreover, in the WHO report on self-directed violence (2002), we find the notion “suicidal behaviour”: “Suicidal behaviour ranges in degree from merely thinking about ending one’s life, through developing a plan to commit suicide and obtaining the means to do so, attempting to kill oneself, to finally carrying out the act (‘completed suicide’)”.
Par ailleurs, dans le rapport de l’OMS sur la violence dirigée contre soi (2002), nous retrouvons la notion de « comportements suicidaires »: « Les comportements suicidaires vont de la simple pensée de mettre fin à ses jours à la préparation d’un plan pour se suicider et à l’obtention des moyens nécessaires pour le mettre à exécution, à la tentative de suicide elle-même, pour finir par le passage à l’acte (“suicide abouti”) ».

Marketing & Sales expenses fell to 29.0% of net sales in 2009 from 30.0% in the 2008 period while supporting the global rollouts of a range of new products, including Galvus, Exelon Patch, Tekturna/Rasilez and Afinitor.
Les dépenses de Marketing et vente ont diminué à 29,0% du chiffre d’affaires net, contre 30,0% durant la période comparable de 2008, tandis qu’une série de nouveaux produits a été commercialisée dans le monde entier, notamment Galvus, Exelon Patch, Rasilez/Tekturna et Afinitor.

Recent estimates of the cost attributable to MRSA infection in hospitalised patients ranged from 10 000 to 36 000 Euros.
On a récemment estimé que le coût imputable à l'infection à MRSA chez les patients hospitalisés est compris entre 10 000 et 36 000 Euros.

Nevertheless, some studies, including the 2004 Belgian Health Survey discussed above, throw some light on this problem in so far as they focus on measuring notions such as psychological illbeing (Book II of the Health Interview Survey – Belgium 2004, pp 204-209): “The psychological well-being assessed in the 2004 Belgian Health Survey is measured by means of an instrument (GHQ-12, General Health Questionnaire) that uses scores ranging from 0 to 12. A higher score indicates a higher probability/severity of psychological ill-being.
« Le bien-être/mal-être psychologique évalué dans l’enquête de santé en Belgique de 2004 est mesuré grâce à un outil (GHQ-12, General Health Questionnaire) dont l’échelle de mesure va de 0 à 12, où un score plus élevé indique une plus grande probabilité/sévérité du mal-être psychologique.